Navigation Links
Moffitt Cancer Center researchers unravel biochemical factor important in tumor metastasis
Date:11/9/2011

TAMPA, Fla. -- A protein called "fascin" appears to play a critical transformation role in TGF beta mediated tumor metastasis, say researchers at Moffitt Cancer Center in Tampa, Fla., who published a study in a recent issue of the Journal of Biological Chemistry.

According to study corresponding author Shengyu Yang, Ph.D., of Moffitt's Comprehensive Melanoma Research Center and the Department of Tumor Biology, elevated Transforming Growth Factor beta in the tumor microenvironment may be responsible for fascin over-expression, which in turn can promote metastasis in some metastatic tumors.

TGF beta is a versatile cytokine involved in many physiological and pathological processes in adults and in the developing embryo, including cell growth, cell differentiation, cell death (apoptosis) and cellular homeostasis. TGF beta is best known as a tumor suppressor, exerting growth inhibitory roles in normal tissue and early stage tumors. However, many metastatic tumors are able to overcome the growth inhibition and secreted elevated levels of TGF beta to promote tumor metastasis. How TGF beta promotes metastasis is not completely understood. The authors suggested that fascin may be the key to understand the pro-metastasis function of TGF beta, as fascin knockdown almost completely abolished TGF beta induced tumor cell migration and invasion.

The researchers explained that fascin levels are low or not detected in normal tissues, but are highly elevated in malignant tumors. Also, high fascin expression is associated with poor prognosis. It has been clear for some time, they noted, that there is a causal role for fascin over-expression in tumor cell dissemination. However, the underlying mechanism for the elevation of fascin levels has not been clarified. Their analysis using cell culture- based assay and patient microarray data mining strongly suggests that elevated TGF beta levels in tumors lead to fascin overexpression, which in turn promotes metastasis.

"Our data suggests that fascin is an immediate TGF beta target gene essential for its pro-invasion activity in cancer metastasis," explained Yang.

While there have been many studies on the role of fascin in tumor cell migration and metastasis, the current study is first to report that TGF beta elevates fascin protein expression to promote invasion, particularly in tumor cells of spindle-shaped the kind of morphology associated with high tumor invasiveness and more metastatic disease.

"The finding that TGF beta only induces fascin over-expression in highly metastatic tumor cells is especially interesting," said Yang. "Therapies targeting fascin may block TGF beta mediated metastasis without interfering with the tumor suppressor role of TGF beta in normal tissues."


'/>"/>
Contact: Ferdie De Vega
Ferdinand.DeVega@moffitt.org
813-745-7858
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
2. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
3. Moffitt Cancer Center researchers use new tool to counter multiple myeloma drug resistance
4. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
5. Moffitt Cancer Center researchers find more clues to causes of breast cancer
6. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
7. Enhancing arrest of cell growth to treat cancer in mice
8. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
9. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
10. Low forms of cyclin E reduce breast cancer drugs effectiveness
11. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
Breaking Medicine Technology: